Skip to main content
Journal cover image

Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms.

Publication ,  Journal Article
Reinke, EK; Lee, J; Zozulya, A; Karman, J; Muller, WA; Sandor, M; Fabry, Z
Published in: Journal of neuroimmunology
May 2007

The homophilic cell adhesion molecule PECAM-1 is a major participant in the migration of leukocytes across endothelium. We examined the ability of a chimeric soluble PECAM-1 fused to human IgG-Fc to impair leukocyte entry through the blood-brain barrier and reduce CNS autoimmunity. sPECAM-Fc impaired migration of lymphocytes across brain endothelial monolayers and diminished the severity of EAE, an experimental model of MS, when administered at the onset of symptoms. However, in mice transgenic for sPECAM-Fc, the chronically elevated levels of sPECAM-Fc hastened onset of EAE disease without significantly changing clinical score severity. Our data suggest that short-term treatment of diseases like MS with sPECAM-Fc has therapeutic potential.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of neuroimmunology

DOI

EISSN

1872-8421

ISSN

0165-5728

Publication Date

May 2007

Volume

186

Issue

1-2

Start / End Page

86 / 93

Related Subject Headings

  • Time Factors
  • Severity of Illness Index
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Pertussis Toxin
  • Neurology & Neurosurgery
  • Mice, Transgenic
  • Mice
  • Leukocytes
  • In Vitro Techniques
  • Immunoglobulin G
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reinke, E. K., Lee, J., Zozulya, A., Karman, J., Muller, W. A., Sandor, M., & Fabry, Z. (2007). Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms. Journal of Neuroimmunology, 186(1–2), 86–93. https://doi.org/10.1016/j.jneuroim.2007.03.014
Reinke, Emily K., Jangeun Lee, Alla Zozulya, Jozsef Karman, William A. Muller, Matyas Sandor, and Zsuzsanna Fabry. “Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms.Journal of Neuroimmunology 186, no. 1–2 (May 2007): 86–93. https://doi.org/10.1016/j.jneuroim.2007.03.014.
Reinke EK, Lee J, Zozulya A, Karman J, Muller WA, Sandor M, et al. Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms. Journal of neuroimmunology. 2007 May;186(1–2):86–93.
Reinke, Emily K., et al. “Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms.Journal of Neuroimmunology, vol. 186, no. 1–2, May 2007, pp. 86–93. Epmc, doi:10.1016/j.jneuroim.2007.03.014.
Reinke EK, Lee J, Zozulya A, Karman J, Muller WA, Sandor M, Fabry Z. Short-term sPECAM-Fc treatment ameliorates EAE while chronic use hastens onset of symptoms. Journal of neuroimmunology. 2007 May;186(1–2):86–93.
Journal cover image

Published In

Journal of neuroimmunology

DOI

EISSN

1872-8421

ISSN

0165-5728

Publication Date

May 2007

Volume

186

Issue

1-2

Start / End Page

86 / 93

Related Subject Headings

  • Time Factors
  • Severity of Illness Index
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Pertussis Toxin
  • Neurology & Neurosurgery
  • Mice, Transgenic
  • Mice
  • Leukocytes
  • In Vitro Techniques
  • Immunoglobulin G